Example only · Decision report
Should we license an aging-mechanism asset now?
Recommendation: do not enter licensing negotiations yet. In this fictional investigation, no asset clears all six tests. The next useful action is to resolve access to data and supply before commissioning a trial model.
1 · What the customer asked
Find an oral asset acting on an aging mechanism, with readable Phase 1 or Phase 2 human data and an outpatient proof-of-concept path. Hypothetical next-experiment ceiling: $250,000. Current-status checks: within 30 days. Geography: Australia or the U.S. Licensing budget: not yet set.
Those numbers illustrate customer inputs. They are not recommended budgets or freshness settings.
2 · What the investigation established
| Illustrative workflow result | Count | Meaning |
|---|---|---|
| Candidate records examined | 6 | Within the agreed limit of ten |
| Qualified assets | 0 | No asset satisfies every mandatory test |
| Internal research | 5 | Identity, current access or other necessary evidence remains unresolved |
| Excluded from this mandate | 1 | A documented disqualifying efficacy result, once evidence was sufficient to judge |
No research or excluded asset is presented as a recommendation. Actual reports include source-backed findings, not these invented counts.
3 · The questions that control the next decision
| Unresolved question | Evidence needed | Consequence |
|---|---|---|
| Can the required rights be obtained? | Current, indication-specific authority to license; data, regulatory files and supply covered separately | Unknown access stays in research. Confirmed unreachable rights fail. |
| Was the programme shelved for funding or because it failed? | Current sponsor disclosure reconciled with completed clinical results | A funding narrative cannot erase a confirmed disqualifying failure. |
| Can a credible experiment fit the ceiling? | A supported design and itemized costs, including manufacturing and required oversight | Unknown cost stays in research. Supported cost above the ceiling fails this mandate. |
4 · Cheapest credible next step
First establish who controls the data and supply. If authorized, request an inventory and current access terms. Do not commission a dosing study based on a patent-owner name alone.
Trial cost: not established. A defensible model needs a dose, eligible population, endpoint, duration, design rationale, supply route and site/vendor assumptions. This report does not fill the gap with an attractive invented number.
Continue if: current evidence establishes reachable access and a credible experimental path within the mandate. Stop if: rights are demonstrably unreachable or a required test has a confirmed failure.
5 · What a qualifying asset's one-pager contains
- Exact asset, indication, programme and current rights holder.
- PASS on each of six tests, with supporting and contrary evidence.
- A preliminary trial model: endpoint, timing, design assumptions, itemized cost range and unresolved inputs.
- Specific next action and go/stop rules.
- Source links, publication dates, checked dates and what was actually verified.
No asset one-pager is supplied in this example because none qualifies. A real qualifying dossier must carry real evidence; this page is not evidence.
6 · The evidence ledger
Actual reports distinguish the date a study was published from the date current status or ownership was verified. Each material claim links to its source and the relevant passage. Contrary results remain visible. There are no invented citations in this illustration.